Ibrolipim

Drug Profile

Ibrolipim

Alternative Names: NO 1886; OPF 009

Latest Information Update: 12 Feb 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Otsuka Pharmaceutical
  • Developer TAP Pharmaceutical Products
  • Class Antihyperglycaemics; Antihyperlipidaemics; Obesity therapies; Small molecules
  • Mechanism of Action Lipoprotein lipase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetic complications; Hypertriglyceridaemia; Low HDL cholesterol; Nephrotic syndrome; Obesity

Most Recent Events

  • 08 Mar 2004 No development reported - Phase-II for Hypertriglyceridaemia in Japan (unspecified route)
  • 08 Mar 2004 No development reported - Phase-II for Low HDL cholesterol in Japan (unspecified route)
  • 08 Mar 2004 No development reported - Phase-II for Obesity in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top